Reportstack has announced a new market research publication on Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014 which provides elemental information and data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastroesophageal (GE) Junction Carcinomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by team of industry experts.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Companies Mentioned
AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Amgen Inc., Novartis AG, Bristol-Myers Squibb Company, Eli Lilly and Company, C. H. Boehringer Sohn AG & Co. KG, Dainippon Sumitomo Pharma Co., Ltd., Aphton Corporation , Amgen research GmbH, National Cancer Institute, North Central Cancer Treatment Group, Stanford University, Sidney Kimmel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Southwest Oncology Group, University of Pittsburgh, Fox Chase Cancer Center, The University of Texas M. D. Anderson Cancer Center.
To view the table of contents and know more details please visit Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014.
No comments:
Post a Comment